Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)
The purpose of this study was to evaluate the efficacy (progression free survival (PFS) and response rate) and safety of vinorelbine and trastuzumab combination chemotherapy in patients with HER2-overexpressing, metastatic breast cancer as a first line chemotherapy regimen. Patients with histologically confirmed, HER2-positive (immunohistochemistry (ICH) 3+, or 2+ and FISH+) metastatic breast cancer who had nor received prior vinorelbine or anti-HER2 therapy in the adjuvant setting, received at least eight weeks of vinorelbine i.v. (25 mg/g weekly) and trastuzumab (4 mg/kg on day 1 followed by 2 mg/kg weekly). Forty-one women from six participating centers were enrolled into the trial. The overall response rate, was 43.9% (18 of 41 patients), (CI 28–60.3%), 30% of patients were progression free after 1 year. Four patients reached complete remission, 14 partial remission and five had stable disease for at least 18 weeks. Six patients developed primary progression. 35 patients (85%) experienced progression after a median time of 235 days. Therapy was in general well-tolerated. There were two CTC grade 4 infusion syndromes and two patients experienced cardiotoxicity at least grade 2. This phase II trial of vinorelbine and trastuzumab demonstrated an effective and well-tolerated regimen with a favourable safety profile.
Metastatic breast cancer Phase II trial Vinorelbine Trastuzumab
This is a preview of subscription content, log in to check access.
We thank all participating patients and attending medical staff in the different centers, Klaus Pahnke, Büro für Statistik, Reinheim, Germany for statistical analyses and the monitors of GSO-Gesellschaft für Studienmanagement und Onkologie mbH, Hamburg, Germany. Financial support was provided by Pierre Fabre Pharma GmbH, Freiburg, Germany and Hoffmann-La Roche AG, Grenzach-Wyhlen, Germany.
Cobleigh MA et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9):2639–2648PubMedGoogle Scholar
Baselga J et al (1999) Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26(4 Suppl 12):78–83PubMedGoogle Scholar
Gianni L et al (1995) Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87(15):1169–1175. doi:10.1093/jnci/87.15.1169PubMedCrossRefGoogle Scholar
Seidman AD et al (1995) Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13(10):2575–2581PubMedGoogle Scholar
Burstein HJ et al (2003) Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumour markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21(15):2889–2895. doi:10.1200/JCO.2003.02.018PubMedCrossRefGoogle Scholar
Burstein HJ et al (2007) Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbin or taxane study. Cancer 110(5):965–972. doi:10.1002/cncr.22885PubMedCrossRefGoogle Scholar
Franquesa R, Centelles M, Villadiego K (2005) A multicenter study of trastuzumab (H) and vinorelbine (N) as first and second line therapy for patients with HER2-positive metastatic breast cancer (HER2+ MBC). ASCO Meeting Abstracts, 868Google Scholar
Jahanzeb M et al (2002) Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 7(5):410–417PubMedCrossRefGoogle Scholar
Burstein HJ et al (2001) Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19(10):2722–2730PubMedGoogle Scholar
Porta V, Martin M, Gil M (2004) Evaluation of vinorelbine (N) and trastuzumab (H) as first line therapy for HER2-positive metastatic breast cancer (HER2+ MBC): impact on clinical response and cardiac function. ASCO Meeting Abstracts: 636Google Scholar